Home   /  Find a Trial  /  See All Trials HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

see All Trials

Sort by zip code:  




18 trials contain the search term(s): "registry" OR "survey"

Carboplatin with Other Chemotherapy Drugs Before Surgery for Triple Negative Breast Cancer

Randomized, Open Label, Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by AC in Stage I-III Triple-negative Breast Cancer (NCT02413320)


Carboplatin (Paraplatin®) is a platinum-based chemotherapy drug used to treat advanced breast cancer that has not responded to previous chemotherapy treatments. Paclitaxel (Taxol®) and docetaxel (Taxotere®) are chemotherapy drug commonly used to treat advanced breast cancer. Doxorubicin (Adriamycin®) and cyclophosphamide (Cytoxan®)--known as AC--is routinely used to treat breast cancer. Giving chemotherapy before surgery--called neoadjuvant treatment--allows researchers to study how the tumor responds to the treatment regimen. Previous studies have found that Paraplatin and Taxotere are well tolerated in the neoadjuvant setting. This study is comparing the safety and effectiveness of Paraplatin and Taxol followed by AC with Paraplatin and Taxotere when given before surgery to women with early stage triple negative breast cancer. To be eligible, participants must be enrolled in the Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry (PROGECT).
This is a Phase II trial

Lumpectomy and Radiofrequency Ablation

ABLATE Registry: Radiofrequency Ablation After Breast Lumpectomy (eRFA) Added To Extend Intraoperative Margins in the Treatment of Breast Cancer (NCT01153035)


During a lumpectomy, the surgeon removes the tumor as well as some tissue surrounding the tumor. After the surgery, if the pathologist finds that there were cancer cells near the edges (margin) of the removed tissue, a second operation may be needed to remove more tissue. Radiofrequency ablation is a procedure that uses heat generated by an electrical current to destroy tumor tissue. Researchers believe that radiofrequency ablation given during a lumpectomy may help to ensure that no cancer remains in the margins. This may reduce the need for a second surgery. It also may reduce the chance of a local recurrence. The purpose of this trial is to see if lumpectomy followed by radiofrequency ablation reduces the need for a second surgery. To be eligible, participants must be planning to receive a lumpectomy.

Breast Seed Implant Radiation Treatment for Women with DCIS or Early-Stage Breast Cancer

A Multicenter Registry Study of Breast Microseed Treatment for Early Stage Breast Cancer (NCT02701244)


To take part in this study, you must be age 50 or older and have had breast conserving surgery (lumpectomy) along with an axillary node dissection (minimum 6 nodes sampled) or sentinel lymph node biopsy for DCIS or early stage (stage I-III) breast cancer. This study is investigating the safety and effects (good and bad) of a permanent breast seed implant (PBSI) radiation technique for treating women with DCIS or early-stage breast cancer. PBSI involves implanting radioactive seeds in a portion of the breast, allowing the patient to live a normal life while the seeds deliver the prescribed radiation to the breast. Researchers think that PBSI is a safe and effective alternative to traditional forms of radiation for women who have had a lumpectomy and lymph node dissection or sentinel lymph node biopsy.

Targeted Intraoperative Radiotherapy (TARGIT) Registry Trial

Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery (NCT01570998)


Radiation is used to kill any breast cancer cells that may not have been removed during surgery. Targeted intraoperative radiotherapy is delivered during surgery immediately after the tumor has been removed. This allows the radiation to accurately target the tissue surrounding the tumor, where the risk of recurrence is highest. It takes about 20-35 minutes to provide intraoperative radiotherapy. This study, the Targeted Intraoperative Radiotherapy Trial (TARGIT), will follow women who receive this type of radiation therapy for five years, allowing researchers to study its effectiveness and side effects. This registry trial is open to patients who are receiving a lumpectomy (breast conserving surgery) and who are considered to be at low risk of having a local recurrence. If indicated, participants will also receive whole breast radiation.

Using Telemedicine for Genetic Counseling for the BRCA1/2 Mutations

A Randomized Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services (NCT02517554)


To take part, you must be at high risk for having the BRCA mutations that increase breast and ovarian cancer risk. You must also have insurance coverage for genetic testing. Telemedicine (telephone and videoconferencing) may provide a way to offer genetic counseling to women who do not have a genetic counselor in their area. This study will allow researchers to learn if using telemedicine to deliver genetic counseling works as well as in-person genetic counseling sessions.

Computer and Internet-Based Support Program for Asian-American Breast Cancer Survivors

To Enhance Breast Cancer Survivorship of Asian Americans (NCT02803593)


To take part in this study, you must have been diagnosed with breast cancer within the past 5 years and must self-identify as Chinese, Korean, or Japanese. You must also have access to the internet through a computer or mobile device (smartphone or tablet). This study will evaluate whether an internet and computer-based information and coaching/support program designed specifically for Asian-American breast cancer survivors improves quality of life. The program is provided in English, Mandarin Chinese, Korean, and Japanese.

A Pregnancy Registry for Women on HER2-Targeted Therapies

An Observational Study of Pregnancy And Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta In Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior To Conception (NCT00833963)


Trastuzumab (Herceptin®), pertuzumab (Perjeta®) and ado-trastuzumab emtansine (Kadcyla®) are used to treat HER2-positive tumors. These drugs are not approved for use during pregnancy and carry labels that advise women to avoid becoming pregnant or breastfeeding. The MotHER Pregnancy Registry is a U.S.-based, prospective, observational study in women with breast cancer who received at least one dose of these drugs during pregnancy or within 6 months of conception. The primary objective of this Pregnancy Registry is to monitor women who were pregnant when receiving any of these medications to determine the frequency of adverse pregnancy complications or major birth defects.

A Study of the Inherited KRAS-Variant Mutation and Breast Cancer Risk

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment (NCT02253251)


Researchers have identified an inherited genetic mutation—a KRAS-variant—that may increase a person's risk of developing breast or other types of cancer. This study will follow participants for 10 years in order to analyze the association between the KRAS-variant mutation and cancer risk. The researchers will also look at the effect that different lifestyle factors have on cancer risk. All participants will have a saliva sample tested for the KRAS-variant. To be eligible, participants must have a personal or family history of breast cancer.

Adherence to Aromatase Inhibitors in HR+ Stage I-III Latina & Other Breast Cancer Patients

Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors - (AIs) (NCT03144037)


To take part in this study, you must be a postmenopausal women who is taking an aromatase inhibitor (AI) after surgery to treat HR+ (ER+/PR+) stage I-III breast cancer. This study will help researchers learn more about how well women on AI hormone therapy adhere to their treatment regimen. The researchers are making an effort to recruit Latinas who are being treated at Texas Tech University Health Sciences Center in El Paso for this study, but women of all ethnic groups can take part.

iCaRe2: Integrated Cancer Data Repository for Cancer Research

Integrated Cancer Repository for Cancer Research (NCT02012699)


This study is open to all women and men who have--or have not--had cancer. To take part in this study, you must be at least 19 years old. Study participants will provide blood, urine and tissue samples for a biobank. These specimens will be used by cancer researchers to learn more about cancer risk factors, cancer prevention, early detection and personalized cancer treatments.

NCI's Exceptional Responder Registry

A Basket Study: Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders (NCT02243592)


Some cancer patients get better from treatments that didn't work for most patients with their type of tumor. These people are often referred to as exceptional responders. Learning more about the molecular makeup of these patients' tumors may help researchers determine why a treatment worked--and who else might benefit. This study is collecting information about patients with breast and other types of tumors who are considered exceptional responders to their treatment.

  • Participation TimeNumber of visits unavailable
  • Participating research sites
    Research sites: 0 sites total Contact information

Study of Women 50 and Over Who Get CyberKnife Radiation for DCIS or Stage I Breast Cancer

A Multi-Institutional Registry for CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI) (NCT02457117)


There are different types of radiation therapy women can receive as part of their breast cancer treatment. CK-SAPBI (CyberKnife® Stereotactic Accelerated Partial Breast Irradiation) is a type of radiation therapy that delivers a targeted, high dose of radiation over a short period of time with limited damage to surrounding healthy tissue. Results from early studies suggest CK-SAPBI technique is as safe and effective as traditional whole breast radiation. Researchers are establishing a registry for women who are age 50 and older who have received CK-SAPBI therapy and will follow these women for five years. This registry will allow the researchers to collect information about the effectiveness and cosmetic outcomes seen with CK-SAPBI.

Inflammatory Breast Cancer Registry

Inflammatory Breast Cancer (IBC) Registry (NCT00477100)


Inflammatory breast cancer is a rare, aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin, causing the breast to appear red and swollen. Researchers have not yet identified any genes or other risk factors that they could use to design better treatments for inflammatory breast cancer. The goal of this study is to collect blood and tissue samples and clinical data from patients with untreated newly diagnosed inflammatory breast cancer. The samples and data will be stored in a research tissue bank and used to help researchers learn more about inflammatory breast cancer.

A Registry for Patients with a Breast Cancer Genetic Mutation or Triple Negative Tumor

PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations (NCT02302742)


Women and men who carry an inherited genetic mutation are at increased risk of developing breast cancer. BRCA1 and BRCA2 are the most common genetic mutations associated with breast cancer risk. But there are other mutations that also increase breast cancer risk, including PTEN, P53, PALB2, and others. Previous studies have found that individuals with triple-negative breast cancer are likely to carry the BRCA mutation. This registry study will collect cancer-related information from individuals with triple negative breast cancer and/or inherited genetic mutations. The information collected in the registry will be used to learn more about the relationship between genetic mutations and cancer outcomes in individuals with triple negative breast cancer.

Patient Navigation for Breast/Cervical Cancer Screening for Muslim-American Women in NYC

Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City (NCT03081507)


To take part in this study, you must identify as Muslim, live in New York City and not have been diagnosed with breast or cervical cancer. It must also be more than two years since you had a mammogram. This study is investigating whether a patient navigation program designed specifically for Muslim-American women increases their participation in screening programs for breast and cervical cancer.

Treating Advanced Cancer By Choosing Targeted Therapy Based on Tumor's Genetic Makeup

A Basket Study: Targeted Agent and Profiling Utilization Registry (TAPUR) Study (NCT02693535)


This study is evaluating the safety and effectiveness of using the tumor's genetic alterations to select an FDA-approved targeted therapy for treatment. In this study, the targeted therapy each patient receives will be selected based on their tumor's specific genetic profile. To be eligible, individuals must have no available standard therapy options. This study is enrolling patients with advanced breast and other cancers.

Targeted Therapy Recommendation Based on Genomic Profiling

A Basket Study: Registry Study for Personalized Cancer Therapy (NCT02508662)


To take part in this study, you must have advanced (some stage III) or metastatic (stage IV) breast cancer and have already received a treatment that your cancer progressed on or did not respond to. If you take part in this study, researchers will review your medical records to learn about your tumor's genomic profile. This information will be used to recommend a targeted drug that is FDA-approved for patients who don't have breast cancer but do have tumors with the same genomic profile. This study is also recruiting patients with other types of advanced cancer.

Study of Relationship Between Oral/Gut Microbiomes and Breast Cancer

Role of the Oral and Gut Microbiomes in Breast Cancer (MAN001)


Bacteria found in our mouth and our guts may provide information about our overall health. This study is investigating whether bacteria in the mouth or gut have any relation to breast cancer. For the study, researchers will compare bacterial DNA from cheek and stool samples provided by women with breast cancer and healthy women. This study is open to women with DCIS and invasive breast cancer who will be starting treatment. It is also open to healthy women. Women who have been treated for a prior cancer or DCIS are not eligible. For breast cancer patients, the bacteria samples can be provided after surgery. However, they must be provided before starting chemotherapy, hormone therapy, targeted therapy or radiation.